Lu C, et al. - Via 29 randomized clinical trials that recruited 10,204 members and 17 treatments, of disease-modifying antirheumatic drugs (DMARDs) (tofacitinib, apremilast) as well as biological DMARDs (guselkumab, ustekinumab, secukinumab, ixekizumab, brodalumab, clazakizumab, abatacept, adalimumab, etanercept, infliximab, certolizumab, and golimumab), the experts intended to review and examine the comparative efficiency and security of targeted DMARDs for active psoriatic arthritis (PsA). In comparison to the placebo, during induction therapy, in order to obtain ACR20 and psoriasis area and severity index (PASI75), all treatments except clazakizumab were more effective. For severe adverse events among all treatments, no meaningful difference was exhibited, however, a higher rate of adverse events of tofacitinib, apremilast, and ixekinumab 80 mg every 2 weeks were observed. In accomplishing both ACR20 and PASI75, infliximab, golimumab, etanercept, adalimumab, guselkumab, and secukinumab 300 mg exceeded other drugs. Therefore, infliximab, guselkumab, adalimumab, golimumab, secukinumab (300 mg and 150 mg), and ustekinumab (45 mg and 90 mg) were identified by both great efficiency and safety. In the analysis among biologic-naïve patients, the same rankings were seen. However, when contrasted with placebo, ustekinumab, secukinumab (300 mg and 150 mg), ixekizumab, abatacept, certolizumab pegol, tofacitinib, and apremilast were still related with higher ACR20 while ustekinumab, secukinumab (300 mg), ixekizumab and tofacitinib were linked to greater PASI75 among biologic-experienced/failed patients. Hence, for active PsA during induction therapy, regarding the overall risk-benefit profile, infliximab, guselkumab, adalimumab, golimumab, secukinumab, and ustekinumab could be safer and more effective treatments in comparison to that of other targeted DMARDs.